Amazon moves into the prescription business

Does Amazon’s purchase of Pillpack really mark a turning point for the online shopping giant?

Amazon CEO, Jeff Bezos
Source: Bloomberg

Amazon's purchase of US firm Pillpack seems to represent the kind of move that we have seen before from the online giant. Once it has identified an area of potential growth, it either takes over a firm in that zone or moves in with its own infrastructure, undercutting existing firms by offering lower prices. This strategy is underpinned by the wonderful cash generation abilities of the Amazon Web Services division, which gives Amazon CEO Jeff Bezos and co. the ability to rapidly displace its rivals.

Will online pharmacies now go the way of bookshops, losing out to a firm with deeper pockets? Certainly a competitor to Amazon will have a difficult time matching the resources the firm can throw into any sustained campaign.

But Amazon’s triumph in this sector is not a given. Pillpack gets its products from AmerisourceBergen and Walgreens, and the latter is attempting to buy the former. This could be a potential problem should Amazon opt to battle Walgreens for dominance. Amazon’s new pharmacy may find it difficult to strike deals with some firms offering drugs, since it undercuts their own service.

In addition, Pillpack is a very small player. Pillpack’s sales last year were around $100 million, compared to $34.3 billion at Walgreens. Walgreens succeeds because it has a health plan that allows it to issue prescription drugs. Amazon would either need a pill plan or a pharmacy benefit management system that would offer a means of offering drugs through prescription plans.

This market is already under pressure, causing a reduction in margins. It would also increase the regulatory burden, so while Amazon would derive advantages from integrating the Pillpack business with its Prime offering, it would face increased costs.

The Pillpack acquisition is a first step, but it is only that. More infrastructure and possibly an additional merger and acquisition (M&A) is needed to secure Amazon’s place in the online pharmacy sector.

This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.

CFD’s zijn complexe instrumenten en brengen vanwege het hefboomeffect een hoog risico mee van snel oplopende verliezen. 79% van de retailbeleggers lijdt verlies op de handel in CFD’s met deze aanbieder.
Het is belangrijk dat u goed begrijpt hoe CFD's werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
CFD’s zijn complexe instrumenten en brengen vanwege het hefboomeffect een hoog risico mee van snel oplopende verliezen.